Murae Organisor Past Earnings Performance
Past criteria checks 1/6
Murae Organisor's earnings have been declining at an average annual rate of -3.2%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been declining at an average rate of 44.9% per year. Murae Organisor's return on equity is 0.2%, and it has net margins of 8.5%.
Key information
-3.2%
Earnings growth rate
-9.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | -44.9% |
| Return on equity | 0.2% |
| Net Margin | 8.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Murae Organisor makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 11 | 1 | 1 | 0 |
| 31 Mar 24 | 25 | 1 | 2 | 0 |
| 31 Dec 23 | 41 | -9 | 4 | 0 |
| 30 Sep 23 | 48 | 4 | 4 | 0 |
| 30 Jun 23 | 115 | 13 | 1 | 0 |
| 31 Mar 23 | 149 | 20 | 4 | 0 |
| 31 Dec 22 | 173 | 11 | 1 | 0 |
| 30 Sep 22 | 210 | 6 | 0 | 0 |
| 30 Jun 22 | 223 | 63 | 0 | 0 |
| 31 Mar 22 | 210 | 22 | 0 | 0 |
| 31 Dec 21 | 158 | 49 | 3 | 0 |
| 30 Sep 21 | 136 | 37 | 4 | 0 |
| 30 Jun 21 | 246 | -28 | 5 | 0 |
| 31 Mar 21 | 411 | 1 | 5 | 0 |
| 31 Dec 20 | 552 | -14 | 4 | 0 |
| 30 Sep 20 | 660 | -7 | 4 | 0 |
| 30 Jun 20 | 606 | 6 | 4 | 0 |
| 31 Mar 20 | 551 | 18 | 4 | 0 |
| 31 Dec 19 | 577 | 21 | 3 | 0 |
| 30 Sep 19 | 569 | 11 | 4 | 0 |
| 30 Jun 19 | 538 | 14 | 5 | 0 |
| 31 Mar 19 | 507 | 17 | 5 | 0 |
| 31 Mar 18 | 354 | 9 | 3 | 0 |
| 31 Mar 17 | 233 | 2 | 3 | 0 |
| 31 Mar 16 | 186 | 1 | 5 | 0 |
Quality Earnings: 542724 has high quality earnings.
Growing Profit Margin: 542724's current net profit margins (8.5%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 542724's earnings have declined by 3.2% per year over the past 5 years.
Accelerating Growth: 542724's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 542724 had negative earnings growth (-93.3%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: 542724's Return on Equity (0.2%) is considered low.